Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio Medica LaboratoriesNSE:BMLL +1.21%18 Debt-to-EBITDA is 0.97 as of Mar. 2025, which is 47% below its 10-year median of 1.84. GuruFocus rates NSE:BMLL with a GF Score™ of 18/100. The stock has 7 warning signs investors should review. Among 473 Medical Devices & Instruments companies, Bio Medica Laboratories ranks better than 58.35% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Bio Medica Laboratories's Debt-to-EBITDA or its related term are showing as below:
NSE:BMLL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.97 Med: 1.84 Max: 5.73
Current: 0.97
During the past 3 years, the highest Debt-to-EBITDA Ratio of Bio Medica Laboratories was 5.73. The lowest was 0.97. And the median was 1.84.
NSE:BMLL's Debt-to-EBITDA is ranked better than 58.35% of 473
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs NSE:BMLL: 0.97
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Bio Medica Laboratories Debt-to-EBITDA Related Terms
Bio Medica Laboratories Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Medica Laboratories Debt-to-EBITDA Chart
Bio Medica Laboratories Annual Data
Trend
Mar23
Mar24
Mar25
Debt-to-EBITDA
5.73
1.84
0.97
Bio Medica Laboratories Semi-Annual Data
Mar23
Mar24
Mar25
Debt-to-EBITDA
5.73
1.84
0.97
NSE:BMLL vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Bio Medica Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Medica Laboratories Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio Medica Laboratories's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bio Medica Laboratories's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is one times the quarterly (Mar. 2025) EBITDA data.
Bio Medica Laboratories (NSE:BMLL) has a Debt-to-EBITDA of 0.97 as of Mar. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bio Medica Laboratories. This is 47% below median its historical median of 1.84. Over the past decade, Bio Medica Laboratories' Debt-to-EBITDA has ranged from 0.97 to 5.73. According to the industry distribution chart, Bio Medica Laboratories ranks #197 out of 473 companies in the Medical Devices & Instruments industry, placing it in the top 41.6%.
Is Bio Medica Laboratories' Debt-to-EBITDA too high?
Bio Medica Laboratories' current Debt-to-EBITDA of 0.97 is 47% below median its 10-year median of 1.84. Over the past 10 years, this metric has ranged from a low of 0.97 to a high of 5.73. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.64. Bio Medica Laboratories' value of 0.97 is 40.9% below this industry median. Based on the distribution chart, Bio Medica Laboratories ranks #197 out of 473 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bio Medica Laboratories has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Bio Medica Laboratories' Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bio Medica Laboratories ranks #197 out of 473 companies for Debt-to-EBITDA. This puts Bio Medica Laboratories in the upper half of its industry. The industry median Debt-to-EBITDA is 1.64. Bio Medica Laboratories' value of 0.97 is 40.9% below this benchmark. Historically, Bio Medica Laboratories' own Debt-to-EBITDA has ranged from 0.97 to 5.73 over the past decade. While the company's 10-year median is 1.84 vs. the industry median of 1.64, Bio Medica Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio Medica Laboratories's current Debt-to-EBITDA of 0.97 is 40.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bio Medica Laboratories. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Medica Laboratories's current Debt-to-EBITDA is 0.97, which is 47% below median its own 10-year median of 1.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Medica Laboratories stock overvalued right now?
Bio Medica Laboratories (NSE:BMLL) has a current Debt-to-EBITDA of 0.97. The current Debt-to-EBITDA is 0.97, which is 47% below median its 10-year median of 1.84 and 40.9% below the Medical Devices & Instruments industry median of 1.64. Bio Medica Laboratories' overall GF Score™ is 18/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Bio Medica Laboratories (NSE:BMLL), the current Debt-to-EBITDA is 0.97 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Medica Laboratories Ltd is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The majority of revenue is derived from the sales of Liquid injections. Geographically, it operates predominantly in India, and internationally, it exports to Afghanistan.
18GF Score
Get the complete analysis for NSE:BMLL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BMLL has been successfully added to your 
